Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 1/20 | 0.50 |
| ▸ | AHR | P35869 | 7/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.38 |
| ▸ | RELA | Q04206 | 1/20 | 0.38 |
| ▸ | MAOA | P21397 | 2/20 | 0.38 |
| ▸ | MAOB | P27338 | 2/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.37 |
| ▸ | GABRP | O00591 | 1/20 | 0.36 |
| ▸ | GABRD | O14764 | 1/20 | 0.36 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30695267 | 0.78 | PTPN1 (0.53) | PTPN1AHRALDH1A1NPC1MAPT | |
| SCHEMBL20274092 | 0.78 | PTPN1 (0.53) | PTPN1AHRALDH1A1HSD17B10LMNA | |
| SCHEMBL31231900 | 0.75 | PTPN1 (0.50) | PTPN1ALDH1A1LMNAHTTMAOA | |
| SCHEMBL28572489 | 0.75 | PTPN1 (0.50) | PTPN1AHRALDH1A1HSD17B10LMNA | |
| SCHEMBL2092627 | 0.75 | PTPN1 (0.50) | PTPN1AHRALDH1A1HSD17B10LMNA | |
| SCHEMBL23330765 | 0.75 | PTPN1 (0.50) | PTPN1ALDH1A1LMNAHTTMAOA | |
| SCHEMBL2091508 | 0.75 | PTPN1 (0.50) | PTPN1AHRALDH1A1HSD17B10LMNA | |
| SCHEMBL19700122 | 0.75 | PTPN1 (0.50) | PTPN1AHRALDH1A1HSD17B10LMNA | |
| SCHEMBL31589115 | 0.72 | PTPN1 (0.33) | PTPN1ALDH1A1HTTMAOAMAOB | |
| SCHEMBL15898858 | 0.72 | PTPN1 (0.47) | PTPN1AHRALDH1A1HSD17B10LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118496276-A | Organic electroluminescent material and device | 环球展览公司 | 2024-08-16 | — | — | CN | disclosed |
| US-20240270777-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | UNIVERSAL DISPLAY CORPORATION (US) | 2024-08-15 | — | — | US | disclosed |
| CN-114605411-B | Acridine derivative and application thereof | 上海八亿时空先进材料有限公司 | 2024-03-19 | — | — | CN | disclosed |
| CN-114605411-A | Acridine derivative and application thereof | 上海八亿时空先进材料有限公司 | 2022-06-10 | — | — | CN | disclosed |
| US-20170369511-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | TWELVE THERAPEUTICS, INC. | 2017-12-28 | — | — | US | disclosed |
| WO-2017214269-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INFINITY PHARMACEUTICALS, INC. (US) | 2017-12-14 | — | — | WO | disclosed |
| US-9708348-B2 | Trisubstituted bicyclic heterocyclic compounds with kinase activities and uses thereof | INFINITY PHARMACEUTICALS, INC. (US) | 2017-07-18 | — | — | US | disclosed |
| US-9708348-B2 | Trisubstituted bicyclic heterocyclic compounds with kinase activities and uses thereof | INFINITY PHARMACEUTICALS, INC. (US) | 2017-07-18 | — | — | US | disclosed |
| CN-103703006-B | HCV protease inhibitor | 上海唐润医药科技有限公司 | 2016-08-10 | — | — | CN | disclosed |
| US-20160122365-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | TWELVE THERAPEUTICS, INC. | 2016-05-05 | — | — | US | disclosed |
| US-20160122365-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | TWELVE THERAPEUTICS, INC. | 2016-05-05 | — | — | US | disclosed |
| WO-2016054491-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INFINITY PHARMACEUTICALS, INC. (US) | 2016-04-07 | — | — | WO | disclosed |
| WO-2004069829-A1 | (2S)-2-((PYRIMIDIN-4-YL)AMINO)-4-METHYLPENTANOIC ACID AMINOETHYLAMID DERIVATIVES AS IL-8 RECEPTOR MODULATORS FOR THE TREATMENT OF ATHEROSCLEROSIS AND RHEUMATOID ARTHRITIS | PHARMACOPEIA DRUG DISCOVERY, INC. (US) | 2004-08-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170369511-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | PIK3CA, PIK3CD, PIK3CB | PTPN1 767/4885AHR 1748/4885ALDH1A1 3154/4885 |
| US-20240270777-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | OCIAD2, OCIAD1, AOC2 | PTPN1 4593/4885AHR 690/4885ALDH1A1 53/4885 |
| US-20160122365-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | PIK3CA, PIK3CD, PIK3CB | PTPN1 767/4885AHR 1748/4885ALDH1A1 3154/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.